Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Psoriasis and psoriatic arthritis are chronic inflammatory diseases that significantly affect patients’ quality of life. Not only do these diseases impact patients’ physical well-being, but also detrimentally affect their life socially and psychologically. There are many different patterns of skin and joint involvement. Understanding the pathogenesis of these diseases has evolved greatly in the past few decades. It is now understood that psoriasis and psoriatic arthritis are T cell mediated disorders. A number of proinflammatory cytokines have been suggested as playing a role in the disease mechanism, such as tumor necrosis factor-α and interferon-γ. Other important factors proposed in the pathogenesis of these diseases include the role of genetics and environmental factors. New immunomodulating therapies, which are being developed as our understanding of the involvement of innate and adaptive immunity advances, will provide patients with safer, more effective, long-term, management options.
- Lebwohl M: Psoriasis. Lancet 2003, 361:1197–1204. CrossRef
- Buntin DM, Skinner RB Jr., Rosenberg EW: Onset of psoriasis at age 108. J Am Acad Dermatol 1983, 9:276–277. CrossRef
- Ferrandiz C, Pujol RM, Garcia-Patos V, et al.: Psoriasis of early and late onset: A clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002, 46:867–873. CrossRef
- Roenigk HH: Skin manifestations of psoriasis. In Psoriasis. Edited by Roenigk HH, Maibach HI. New York: Marcel Dekker, Inc; 1991:3–9.
- Galadari H, Fuchs B, Lebwohl M: Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int J Dermatol 2003, 42:231–237. CrossRef
- Winchester R: Psoriatic arthritis. In Dermatology in General Medicine. Edited by Fitzpatrick T, Gisen A, Wolff K, Freedberg I, Austen K. New York: McGraw-Hill, Inc.; 1993:515–527.
- Brockbank J, Gladman D: Diagnosis and management of psoriatic arthritis. Drugs 2002, 62:2447–2457. CrossRef
- Gupta MA, Gupta AK: Quality of life of psoriasis patients. J Eur Acad Dermatol Venereol 2000, 14:241–242. CrossRef
- Christophers E, Sterry W: Epidermis: disorders of cell kinetics and differentiation. In Dermatology in General Medicine. Edited by Fitzpatrick T, Gisen A, Wolff K, Freedberg I, Austen K. New York: McGraw-Hill, Inc.; 1993:489–512.
- Arnold H, Odom B, James W: Andrew’s Diseases of Skin: Clinical Dermatology. Philadelphia: W.B. Saunders Company; 1990.
- Farber EM, Nall L: Pustular psoriasis. Cutis 1993, 51:29–32.
- National Psoriasis Foundation. www.psoriasis.org. Accessed September 19, 2003.
- van de Kerkhof PC, Franssen ME: Psoriasis of the scalp: diagnosis and management. Am J Clin Dermatol 2001, 2:159–165. CrossRef
- Cockayne SE, Messenger AG: Familial scarring alopecia associated with scalp psoriasis. Br J Dermatol 2001, 144:425–427. CrossRef
- Chalmers RJ, O’Sullivan T, Owen CM, Griffiths CE: A systematic review of treatments for guttate psoriasis. Br J Dermatol 2001, 145:891–894. CrossRef
- Fitzpatrick TB, Johnson RA, Wollf K, et al.: Color Atlas and Synopsis of Clinical Dermatology-Common and Serious Diseases. New York: McGraw-Hill; 1997.
- Drew GS: Dermatology-psoriasis. Prim Care 2000, 27:385–406.
- Weinstein GD, Gottlieb AB: Therapy of Moderate-to-Severe Psoriasis. New York: Marcel Dekker, Inc.; 2003. Up-to-date reviews of available traditional and biologic therapies.
- Peters BP, Weissman FG, Maka G: Pathophysiology and treatment of psoriasis. Am J Health Syst Pharm 2000, 57:645–662.
- Green MS, Prystowsky JH, Cohen SR: Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996, 34:911–914. CrossRef
- Kumar B, Saraswat A, Kaur I: Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol 2002, 82:192–195. CrossRef
- Gottlieb AB, Chaudhari U, Baker DG, et al.: The national psoriasis score (NPF-PS) system versus the psoriasis area severity index and physician’s global assessment (PGA): a comparison. J Drugs Dermatol 2003, 3:260–266.
- Krueger JG, Feldman SR, Camisa C, et al.: Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis. J Am Acad Dermatol 2000, 43:281–285. This article outlines the importance of quality of life in assessment psoriasis severity CrossRef
- Michet CJ: Psoriatic arthritis. In Textbook of Rheumatology. Edited by Kelley WN, Harris ED, Ruddy S, Sledge CB. Philadelphia: W.B. Saunders Company; 1993:974–984.
- Gottlieb AB: Psoriasis-immunopathology and immunomodulation. Dermatol Clin 2001, 19:649–657. CrossRef
- Granstein RD: New treatments for psoriasis. N Engl J Med 2001, 345:284–287. CrossRef
- Mehlis SL, Gordon KB: The immunology of psoriasis and biologic immunotherapy. J Am Acad Dermatol 2003, 49(Suppl 2):S44-S50. CrossRef
- Nickoloff BJ: The immunologic and genetic basis of psoriasis. Arch Dermatol 1999, 135:1104–1110. CrossRef
- Kreuger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002, 46:1–23. CrossRef
- Fearon U, Veale DJ: Pathogenesis of psoriatic arthritis. Clin Exp Dermatol 2001, 26:333–337. CrossRef
- Ritchlin CT, Haas-Smith SA, Li P, et al.: Mechanisms of TNF-a and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111:821–831. CrossRef
- Gottlieb AB, Bos JD: Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 2002, 105:105–116. CrossRef
- Gottlieb AB, Krueger JG, Wittkowski K, et al.: Psoriasis as a model for T-cell mediated disease-immunobiologic and clinical effects of treatment with multiple doses of Efalizamab, an anti-CD11a antibody. Arch Dermatol 2002, 138:591–600. CrossRef
- Singri P, West DP, Gordon KB: Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002, 138:657–663. CrossRef
- Gottlieb AB, Masad S, Ramamurthi R, et al.: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatments of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 2003, 48:68–75. CrossRef
- Mehrabi D, Dicarlo JB, Soon SL, McCall CO: Advances in the management of psoriasis: monoclonal antibody therapies. Int J Dermatol 2002, 41:827–835. CrossRef
- Chaudhari U, Romano P, Mulcahy LD, et al.: Infliximab monotherapy in the treatment of plaque-type psoriasis. Lancet 2001, 357:1842–1847. First, double blind, placebo controlled trial of infliximab monotherapy for psoriasis. CrossRef
- Leonardi C, Powers JL, Matheson RT, et al.: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003, 349:2014–2022. CrossRef
- Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis
Current Rheumatology Reports
Volume 6, Issue 4 , pp 306-313
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links